Endurance Exercise for Obesity (ATLAS Trial)

N/A

Recruiting

Led By Lauren Sparks, PhD

Research Sponsored by AdventHealth Translational Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Able to speak and understand written and spoken English

Aged 18-45 years

Must not have

Diagnosis of Type 1 or Type 2 diabetes mellitus

Timeline

Screening 3 weeks

Treatment Varies

Follow Up before and following 12 weeks of deuterium (2h) labelled water administration and either endurance exercise training or control (no exercise)

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to investigate how regular endurance exercise affects the quality of fat tissue and insulin sensitivity in both men and women.

Who is the study for?

This trial is for men and pre-menopausal women aged 18-45 with obesity (BMI of 30.0-40.0), leading a sedentary lifestyle, who haven't had significant weight or lifestyle changes recently. Participants must understand English, agree to use birth control if applicable, and commit to the study's procedures.

What is being tested?

The study investigates how endurance exercise affects fat tissue quality and insulin sensitivity in obese individuals. It involves muscle and fat biopsies, heavy water labeling, glucose clamp tests, monitoring physical activity/dietary habits using an accelerometer.

What are the potential side effects?

Possible side effects include discomfort at biopsy sites, potential risks from endurance exercises like muscle strain or injury, and reactions related to the glucose clamp procedure such as bruising or infection at the needle site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can speak and understand English.

Select...

I am between 18 and 45 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with Type 1 or Type 2 diabetes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ before and following 12 weeks of deuterium (2h) labelled water administration and either endurance exercise training or control (no exercise)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~before and following 12 weeks of deuterium (2h) labelled water administration and either endurance exercise training or control (no exercise)

This trial's timeline: 3 weeks for screening, Varies for treatment, and before and following 12 weeks of deuterium (2h) labelled water administration and either endurance exercise training or control (no exercise) for reporting.